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Abstract While many advanced liver models support hepatic
phenotypes necessary for drug and disease studies, these
models are characterized by intricate features such as co-
culture with one of more supporting cell types or advanced
media perfusion systems. These systems have helped eluci-
date some of the critical biophysical features missing from
standard well-plate based hepatocyte culture, but their ad-
vanced designs add to their complexity. Additionally, regard-
less of the culture system, primary hepatocyte culture systems
suffer from reproducibility issues due to phenotypic variation
and expensive, limited supplies of donor lots. Here we de-
scribe a microfluidic bilayer device that sustains primary
human hepatocyte phenotypes, including albumin production,
factor IX production, cytochrome P450 3A4 drug metabolism
and bile canaliculi formation for at least 14 days in a simple
monoculture format with static media. Using a variety of
channel architectures, we describe how primary cell pheno-
type is promoted by spatial confinement within the
microfluidic channel, without the need for perfusion or co-
culture. By sourcing human hepatocytes expanded in the Fah,
Rag2, and Il2rg-knockout (FRG™-KO) humanized mouse
model, utilizing a few hundred hepatocytes within each chan-
nel, and maintaining hepatocyte function for weeks in vitro
within a relatively simple model, we demonstrate a basic
primary human hepatocyte culture system that addresses
many of the major hurdles in human hepatocyte culture
research.
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1 Introduction
The liver is involved in the course of many infectious and non-
infectious diseases as it maintains hundreds of biological
functions and is the primary organ responsible for activation
and clearance of most therapeutic drugs. While some studies,
such as hepatic drug metabolism and hepatotoxicity screen-
ing, can utilize short-term hepatocyte cultures or liver micro-
somes, long-term culture technologies are needed to model
most liver diseases and their potential therapies (Donato et al.
2008). Previous liver culture studies with the causative agents
of viral hepatitis and malaria have demonstrated that such
models require at least three weeks of continuous host cell
culture (Mazier et al. 1984, Ploss et al. 2010, March et al.
2013). Also, despite their limited availablity and lot-to-lot
variation, these and other studies have found human hepato-
cytes essential in order to properly model both the disease and
the human response to potential therapeutics. Thus, a com-
plete infectious disease liver model for drug discovery should
incorporate a renewable source of human hepatocytes in a
simple, long term, and flexible culture system.
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Many seeding techniques, culture methods, and
microfluidic culture systems have been developed to accom-
plish long-term hepatocyte culture (reviewed in Soldatow
et al. 2013). Media perfusion has been shown to be central
for maintenance of sufficient oxygen transport and appropriate
cytokine gradients, and results in enhanced phenotypic gene
expression from hepatic cell lines (Domansky et al. 2010; Prot
et al. 2011). Primary hepatocyte vesicular transport functions
require cuboidal cell morphology with proper apical and
basolateral surface domains; these domains are established,
in part, by proper interaction with extracellular matrix pro-
teins. Culturing hepatocytes with specific extracellular ma-
trix compositions significantly affects hepatic phenotypes, and
an overlay of extracellular matrix can help maintain cuboidal
morphology and hepatocyte polarization (Flaim et al. 2005,
LeCluyse 2001). Cuboidal cell architecture is also affected by
the culture microenvironment; compaction within a small
channel leads to extended viability (Lee et al. 2007). To enable
multiplexing, maintenance of primary hepatocyte phenotype
in a multiwell format has been achieved and utilized by
patterning hepatocytes in a co-culture with fibroblasts, dem-
onstrating the importance of cell-cell interaction in the design
of high-order culture systems (Bhatia et al. 1997; Khetani and
Bhatia 2008).
While these elements are critical for the development of a
high-order liver model, they also carry drawbacks. Perfusion
often requires integrated pumps and custom-fabricated fluidic
lines. Cells cultured on single component extracellular matri-
ces show matrix lot-specific phenotypes and multicomponent
matrices are often difficult to mix and deposit on surfaces;
requiring additional technologies. Co-cultures require specif-
ic, often proprietary sub-clones of supporting cells and require
much trial and error to optimize seeding logistics and media
compositions. These characteristics make it difficult to incor-
porate several functionalities into one culture system to take
advantage of the additive effects of each mechanism.
To address the challenges of integrating multiple mecha-
nisms into one system for long-term, stable culture of human
hepatocytes, we have designed a microfluidic bilayer device
(MBD) featuring two microfluidic channels separated by a
polydimethylsiloxane (PDMS)membrane.While thisMBD is
capable of media perfusion, zonal deposition of extracellular
matrix, and cell co-culture, we describe how static culture of
hepatocytes in the MDB is sufficient to maintain hepatocyte
phenotype for three weeks, without the need for perfusion or
co-culture. We demonstrate that this phenotype is dependent
on spatial confinement of hepatocytes into a collagen and
fibronectin-coated microphysical space, which is relevant to
a liver sinusoid. To enable comparisons between studies, to
model the human response to novel compounds, and to take
advantage of their potentially unlimited production, we select-
ed commercially available FRG™-KO mouse-expanded hu-
man hepatocytes (FHH’s) as host cells (Azuma et al. 2007,
Strom et al. 2010). This new technology shows promise for
mitigation of risks associated with primary human hepatocyte
lots, particularly their limited availability and reproducibility.
Here we describe an optically accessible and simple, yet
highly adaptable and reproducible liver model. This model
provides a testbed to measure the incremental advantages of
adding important factors such as media perfusion, complex
extracellular matrices, and co-cultures to create an even more
effective liver model. Our overarching goal is to develop and
optimize a platform that recapitulates key hepatocyte pheno-
types for long-term studies of multiple liver-associated dis-
eases, such as hepatitis and malaria, and enables testing of
potential therapies.
2 Materials and methods
2.1 Fabrication
In summary, the MBD consists of a No. 1 glass coverslip
bonded to a 100 μm-thick slab of PDMS featuring a 250-μm-
wide, 7.4-mm-long laminated channel. A 10-μm-thick spun
PDMS membrane, with a 7.25 % total porosity of evenly-
patterned 10-μm-diameter holes, separates the lower and up-
per layers, thus forming bilayer channels. The upper layer
consists of a 500-μm-thick PDMS slab featuring a 500-μm-
wide, 7.4-mm-long cast channel. The two channels originate
in separate areas and run together for 4.1 mm, forming the
bilayer (Fig. 1).
The MBD is assembled by first fabricating the membrane,
upper channel, and lower channel out of PDMS, followed by
plasma bonding of the layers to each other and then to a glass
coverslip. The membrane is fabricated by mixing PDMS base
and curing agent at 10:1 w/w (PDMS, Sylgard® 184, Dow
Corning, Midland, MI, U.S.A.), then degassing the mixture
for 30 min before pouring approximately 1 g onto an SU8
mold featuring 10-μm-tall, evenly spaced posts. The wafer
(treated after initial lithography with (tridecafluoro- 1,1,2,2-
tetrahydroctyl) trichlorosilane (Gelest, Morrisville, PA) for
2 days) is then spun at 500 rpm for 60 s, then 6000
rpm for 250 s (10 s ramp). The spun wafer is placed on a
100 °C hot plate for 10 min, covered in Kapton® and
soaked in IPA before the PDMS membrane is cut and
pulled off the wafer. The lower layer is fabricated from
modified protocols previously described (Epshteyn et al.
2011). Briefly, the lower, laminated layer is manufactured
by pouring 1.2–1.5 g of degassed PDMS (mixed as
above) onto an SU8 wafer with inverse channel features.
The wafer is placed in a laminator with Kapton above the
PDMS, needed for handling the thin and fragile laminated
layer after pressurizing at 35 psi, 60 °C for 30 min. The
upper layer is fabricated by seating an SU8 wafer with
inverse channel features into a petri dish and then pouring
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degassed PDMS (mixed as above) onto the wafer to a height
of 2 mm and allowing it to cure at 65 °C for 90 min. Once
cured, the upper layer containing the cast channel feature is cut
away and inlet/outlet holes are punched with a 1 mm biopsy
punch (Fig. 1).
Final assembly of the microfluidic MBD begins by acti-
vating the lower laminated layer and membrane in a plasma
asher under the following conditions: time: 10 s, RF power:
300 W, vacuum set point: 0.180 torr. The lower laminated
layer and membrane are then pressed together under a
weight at 65 °C for 20 min. The inlet/outlet holes for these
layers are punched with a 1 mm biopsy punch. Then, the
upper cast layer and reverse side of the membrane-lower
layer are activated in a plasma asher (conditions above),
channels and inlet/outlet holes are aligned, and the layers
are pressed together under a weight at 65 °C for 20 min.
Lastly, the PDMS layer stack and a No. 1 glass coverslip
(Dow Corning, Midland, MI, U.S.A.) are activated in a
plasma asher (conditions above) and pressed together. A thin
layer of silicon glue is applied to the outside interface
between PDMS and glass in order to improve MBD rug-
gedness during handling. Completed MBD’s are ethylene
oxide sterilized for 12 h.
2.2 Cell seeding and culture
Stocks of human liver cell line HC-04 (Sattabongkot et al.
2006) were maintained in media consisting of a 1:1 mixture of
F12 andMEM alpha (Life Technologies™, Grand Island, NY,
U.S.A.) supplemented with 0.03 mM Hepes, 551 mg/L l-
Glutamine, and 10 % FBS (Thermo Scientific® Hyclone®,
Waltham, MA, U.S.A.). FHH’s (Yecuris™, Tualatin, OR,
U.S.A.) of the same human donor but from two lots (two
engraftments and harvestings from FRG™-KO mice), were
maintained in Hepatocyte CultureMedium supplementedwith
a SingleQuot™ kit (Lonza, Walkersville, MD, U.S.A.) con-
taining ascorbic acid, fatty acid free BSA, transferrin, insulin,
hEGF and hydrocortisone, prepared per manufacturer’s in-
structions. Human Liver Sinusoidal Endothelial Cells
(HLSEC’s, Sciencell™, Carlsbad, CA, U.S.A.) were thawed
per manufacturer’s instructions onto a 2 μg/cm2 fibronectin-
coated flask (Sigma-Aldrich®, St. Loius, MO, U.S.A.) and
cultured in manufacturer’s complete medium. HLSEC’s were
allowed grow to 90 % confluence in the flask before being
shaken in an orbital shaker at 1000 rpm overnight, to align the
cells and adapt them to shear stress (Fig. S5). All cells were
maintained in a 5 % CO2 incubator at 37 °C.
The net volume of the upper and lower channels of the
MBD is less than 4 μL and cannot be directly accessed by
pipette tips. To enable liquid handling, 0.02 in ID, 0.06 in OD
Tygon® Tubing (US Plastics®, Lima, Ohio, U.S.A.) is
inserted into the slightly smaller diameter inlets and outlets,
creating a tight but temporary seal. A 50 μL HPLC syringe
with a 22 gauge blunt needle is used to perfuse extracellular
matrix solution, media, and cells into the MBD by inserting
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Fig. 1 MBD fabrication and
features. (a) A Spun PDMS
membrane is bonded to a cast
PDMS upper channel and a
laminated PDMS lower channel
before being bonded to a glass
coverslip. (b) Schematic top-view
of channel layout (left);
cross-sectional schematic
(middle) and microscope image
(right) showing device
dimensions and arrangement
of the different layers. Scale bar
represents 100 μm. (c) Complete
device is seated into a 3D-printed
microscope stage adapter.
(d) Device dimensions are thin
enough for high resolution,
individual tubulin strands and
mitochondrion within FHH’s are
noticeable by imaging with a
100x objective but not a 40x
objective. Green: tubulin, red:
mitochondria, blue: DNA. Scale
bars represent 5 μm
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static culture, the tubing is removed from a seeded MBD and
the lower 1 cm of a 1 mL pipette tip (Eppendorf, Hauppauge,
NY, U.S.A.) is cut, sterilized, and inserted into the MBD to
serve as a media reservoir. Four tips, one inserted into each of
the four inlets/outlets, hold about 120 μL of media.
Alternatively, for perfused culture, after cell seeding an ex-
tended piece of Tygon tubing is connect to a syringe by a 22
gauge blunt needle tip. The syringe sits in a syringe pump
(Harvard Apparatus, Holliston, MA, U.S.A.) and a flow rate
of 137 μL/h is equivalent to a shear stress of 0.1 dyn/cm2 at
the cell surface is applied in the lower channel (Fig S3).
TheMBD can support long-term culture of either cell lines,
such as HepG2 and HC-04, or FHH’s. Additionally, theMBD
supports both direct and indirect co-cultures when cells are
seeded together in one channel or separately in either channel
(Fig. 5). Because fibronectin-coated surfaces are recommend-
ed for endothelial cells and collagen-coated surfaces are rec-
ommended for hepatocytes, MBD’s were coated at a calculat-
ed concentration of 5 μg/cm2 collagen and 2 μg/cm2 fibro-
nectin by injecting a solution 1.4 μg/μL rat tail collagen I
(BD™, Waltham, MA, U.S.A.) and 0.6 μg/μL bovine fibro-
nectin (Sigma) diluted in 0.01 N acetic acid into the upper and
lower channels, allowing it to adsorb onto the surface over-
night. For hepatocyte seeding, a vial of cryopreserved human
FHH’s was thawed according to manufacturer’s protocols; for
hepatocyte cell lines, cells are trypsin-released from a flask,
pelleted, and resuspended in complete hepatocyte culture
media to a concentration of 15000 cells/μL (for cell lines) or
8000 cells/μL (for FHH’s). The cell slurry is perfused into the
MBD lower channel with a 50 μL syringe and allowed to
adhere over 3 h before initiation of static culture, described
above. For HLSEC-FHH co-culture experiments, hepatocyte
seeding was preceded by trypsin-releasing aligned HLSEC’s,
concentrating them to 2400 cells/μL, injecting them into the
upper channel, and allowing them to grow to confluence over
2 days under static media. During static MBD culture, media
is changed daily with the appropriate hepatocyte culture me-
dium (for hepatocyte-only cultures) or a 1:1 mixture of hepa-
tocyte culture media and endothelial culture media (for
HLSEC and hepatocyte co-cultures). FHH’s were seeded at
a concentration of 100,000 cells/well into 8-chamber slides
(BD) coated with 5 μg/cm2 rat tail collagen I and 2 μg/cm2
fibronectin, serving as control cultures for albumin produc-
tion, factor IX and bile canaliculi experiments.
2.3 Imaging, sampling, and phenotyping sssays
For high-resolution imaging of FHH’s within the MBD, he-
patocytes cultured for 12 days within the MBD were stained
with 10 μg/mL Hoechst 33342 (Life Technologies), 10 μM
Vybrant Celltracker Red (Life Technologies) and 250 nM
Tubulin Tracker Green (Life Technologies) for 30 min.
Live, stained cells were imaged with a 40x and 100x objective
on a Deltavision Elite (Applied Precision, Issaquah, WA,
U.S.A.) and, for 100x images, were deconvoluted using the
softWoRx® image processing software (Applied Precision).
Assessing bile production was performed by incubatingMBD
cultures with 2 μg/mL 5-(and-6)-Carboxy-2 ′ ,7 ′-
Dichlorofluorescein Diacetate (Carboxy-DCFDA, Life
Technologies) and 10 μg/mL Hoechst 33342 for 10 min,
washing the MBD with complete medium, and imaging live
cells on a Deltavision Elite (Khetani and Bhatia 2008).
HLSEC-hepatocyte co-cultures within the MBD were imaged
by first seeding theMBDwith HLSEC’s and allowing them to
grow to confluence over 2 days before staining with 10 μM
Vybrant® Celltracker Red. Simultaneously, HC-04 hepato-
cytes were stained with 10 μM Vybrant Celltracker Green
within a culture flask before being trypsin-released and seeded
into the vascularized MBD. After attachment, the MBD was
imaged by a Deltavision Elite from coverslip to upper channel
at 1 μm intervals to make a Z-stack; which was further
modeled into polygons in 3D space by the softWoRx image
processing package. Viability staining of cell lines and FHH’s
after long term-flow and static culture was performed with the
Live/Dead® Calcein AM/Ethidium Homodimer kit (Life
Technology) per manufacturer’s protocol.
For albumin and factor IX production assays, media was
collected from the pipette tip reservoirs or 8 chamber slide
wells during daily media changes and frozen at -80 °C until
needed for the ELISA. Samples were loaded into an ELISA
specific for human albumin (Bethyl Labs, Montgomery, TX,
U.S.A.) or human factor IX (Assaypro, St. Charles, MO,
U.S.A.) after diluting 1:10 v/v (for albumin) or 1:5 v/v (for
factor IX) in kit-supplied dilution buffer. ELISA labeling and
washing was performed per manufacturer’s protocols, and
final concentrations were corrected for dilution factor. For
CYP3A4 assays, MBD cultures were induced with 25 mM
Rifampicin (MP Biomedical™, Santa Ana, CA, U.S.A.) or
DMSO for 3 days. The assay was performed with a CYP3A4
P450-Glo™ kit (Promega, Madison, WI, U.S.A.) using a
slight modification to manufacturer’s lytic protocol: MBD’s
were treated with 100 μL of the luciferin reagent for 45 min
and then collected into an opaque plate, followed by 100 μL
of cell lysis reagent injected through the MBD before being
mixed with the previously collected luciferin reagent, to col-
lect both intracellular and extracellular luciferin from the
MBD. Statistics were performed with Prism (Graphpad, La
Jolla, CA, U.S.A.) using multiple student’s t-tests.
3 Results and discussion
3.1 Device design and optimization
Channel materials and dimension were designed around sev-
eral considerations for optimization. First, functional liver
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research is hindered by the cost of primary human hepato-
cytes, regardless of sourcing from human cadavers or further
propagation within the FRG™-KO mouse. Thus, we de-
signed the MBD to hold only 200 hepatocytes per sample,
versus 10,000 or more for conventional well plate-based cul-
ture, such that a single cryovial of hepatocytes could populate
dozens of devices at once. Second, the device was optimized
to allow static culture without perfusion, thus simplifying
device implementation by eliminating the need for syringe
pumps. To minimize diffusion limitations, we shortened the
MBD channel length, compared to a precursor channel de-
scribed in Epshteyn et al. (2011), such that no part of the
channel was more than 5 mm from an inlet. Cells cultured
beyond a threshold of 5 mm from an inlet die; presumably due
to lack of media exchange by diffusion alone during static
culture (Fig. S2). Third, the MBD is meant to represent the
functional unit of the liver. At the cellular level, the liver is
organized into single or double layered sheets of hepatocytes
separated by endothelial cell-lined sinusoids. The lower
channel of the device is approximately 100 μm tall, 250 μm
wide and 4 mm long in the overlapping area. Upon seeding, a
monolayer of primary hepatocytes about four to five cells
wide occupies the length of the channel across from the
vascular upper channel, similar to the liver sinusoid (Fig. 2).
Lastly, long-term culture within a complex, non-well platform
is challenging because the various materials and interfaces
used to manufacture the device are exposed to water for
extended timelines; increasing the opportunity for delamina-
tion. To facilitate lamination by plasma bonding, which results
in much stronger bonds than those obtained with either glue or
silane treatment, a PDMS membrane was developed to yield
an entirely glass and PDMS device (Fig. 1). This membrane
was fabricated using a well-known soft-lithographic molding
process (Jackman et al. 1999); surface treatment and spin-
speeds were optimized to ensure a reproducible fabrication
process with >90 % yield. Successful fabrication of open
holes was verified with SEM (Fig. S1), and the number of
open holes estimated to be ~98 %. PDMS is useful as a
prototyping substrate but is not recommended for studies
involving small molecules because PDMS is known to absorb
hydrophobic molecules; a potential confounder in drug dosing
experiments (Regehr et al. 2009). This model is a prototype
and as the exact architectures and cell types needed for a long-
term liver model are better understood, a future device com-
posed of non-PDMS plastics and manufactured via rapid
prototyping or injection molding would circumvent the nega-
tive properties of a PDMS-based device.
3.2 Long-term maintenance of primary human hepatocyte
phenotypes
Four of the many fundamental roles of hepatocytes are the
production of serum albumin and clotting factor IX,
production and excretion of bile salts, and activation of the
cytochrome P450 enzymes. These phenotypes are lost within
a few days of typical in vitro well-plate culture (Guguen-
Guillouzo et al. 1983; Miao et al. 2000). On the contrary,
primary hepatocytes can maintain their phenotype for≥
3 weeks in the MBD in static culture (no perfusion, with daily
refreshing of the media), without any other supporting cells in
the device. Upon seeding in the lower MBD channel, FHH’s
adhere to the glass coverslip in a monolayer. Over the course
of several days hepatocyte groups ranging from five to twelve
or more cells remodel into multicellular structures, becoming
more cuboidal as observed by microscopy (Figs. 2 & 3). This
remodeling phenomenon appears essential for function, as it is
accompanied with a simultaneous rise in albumin and factor
IX production during the first ten days post seed, which then
stabilizes (Fig. 2). This production level remained stable until
we stopped the experiment 21 days post-seed. Formation of
extracellular bile canaliculi progressed in tandem with the
formation of cuboidal multicellular structures over ten or more
days within the MBD. Bile canaliculi are representative of
hepatocytes maintaining proper polarization, with two
basolateral surfaces separated by an apical belt featuring
transporters for bile salts into canaliculi between neighboring
hepatocytes (Dunn et al. 1991). FHH’s cultured in standard
wells spread and do not produce bile canaliculi (data not
shown, Nakao et al. 2011) but FHH’s cultured within the
MBD formed bile networks visualized by Carboxy-DCFDA;
a dye which fluoresces upon cleavage by hepatic esterases and
is subsequently pumped into bile networks (Fig. 3)
A valid in vitro liver model, especially one designed to
model both the disease and potential treatments, must demon-
strate sustained cytochrome P450 activity to project drug
activation and clearance rates. Quantitative gene expression
measured by RT-PCR is often used to measure many of the
P450 induction levels as many of the dozens of P450 enzymes
can be quantified simultaneously, but this method does not
reveal actual metabolism (Rodríguez-Antona et al. 2001).
Therefore, metabolism of FHH’s withinMBD’s was measured
by cleavage of luciferin from a CYP3A4 substrate after in-
duction with Rifampin over three days. While in standard
well cultures metabolism rapidly drops and becomes non-
existent within days of hepatocyte seeding, expression and
function of CYP3A4 was maintained for at least two weeks
in MBD culture (Fig. 3). While more studies are needed to
validate other P450 enzymes, CYP3A4 is responsible for
metabolism of over 30 % of FDA approved drugs and is
representative of in vitro hepatic drug metabolism
(Guengerich 1999).
Many alternative culture methods utilizing co-cultures, gel
overlays, and perfused channels have demonstrated these
phenomena. However, only the MBD promotes hepatocyte
culture with key hepatocyte phenotypes without co-culture or
perfusion. While unexpected, this result is consistent with
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studies showing that hepatocytes seeded within tubes or cords
demonstrate extended viability (Lee et al. 2007). These
models, however, also feature media perfusion or other ad-
vanced culture methods, confounding the true functional ef-
fect on hepatocytes. Elucidating the essential elements re-
sponsible for maintenance of primary phenotype is critical to
the development of a simple yet effective liver model.
3.2.1 Spatial confinement leads to long-term maintenance
of primary hepatocyte phenotypes
The MBD possesses two key attributes that differ from well
plates, which may be critical for hepatocyte culture: the mi-
crophysical environment provide by the microfluidic channel
(250 μm wide, 100 μm tall), and the small volume of media
available to the cells within the channel. To investigate if one
or both of these differences contribute to maintenance of
hepatic phenotypes, partial devices were constructed with
decreasing complexity. Cells were seeded in a simple channel
architecture, which was subsequently modified to yield either
an open channel with walls but no top (“Confined”) or a
patterned line of cells with no walls (“Patterned”) (Fig. 4a).
A disparity in albumin and factor IX production resulted when
hepatocytes were seeded into a confined space defined by
walls, compared to hepatocytes seeded into a patterned line
without confinement (Fig. 4b). Both device-like cultures
featured 500 μL of media, thus the small volumes of the
MBD do not seem to be sufficient to induce this effect.
(a) (b)
(c) (d) (e)
Fig. 2 Three-week maintenance of albumin secretion and morphology.
(a, b) FHH wellplate and MBD albumin and factor IX output over three
weeks in static culture show a stabilization of primary phenotype in
devices but not wells. Error bars represent standard error of the mean
(SEM) (n=4). (c, d, e) MBD-cultured FHH’s imaged at 5 h, 13 days, and
21 days post-seed, respectively, showing that FHH’s become more cu-
boidal and form multicellular structures, outlined by dotted lines. Scale
bars represent 100 μm
(a)
(b)
Fig. 3 Hepatocyte P450 expression and bile canaliculi formation. (a) At
two weeks post seed of FHH’s in the MBD, bile production identified by
Carboxy-DCFDA dye, which fluoresces upon cleavage by intercellular
esterases and is subsequently pumped into extracellular bile networks,
green: CDF, blue: DNA. (b) Rifampin-induced CYP3A4 expression is
maintained for at least two weeks in MBD culture. Error bars represent
SEM (n=2). Scale bar represents 50 μm
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Microscopy revealed that hepatocytes within the patterned
line were able to spread beyond their initial seeding pattern
(despite the fact that the ECM coating was confined to the
patterned area by the removable channel), in contrast to their
wall-confined counterparts (Fig. 4c). This demonstrates the
primary hepatocyte phenotype is dependent on physical con-
finement of the cells.
Cell concentration and compaction is a well-documented
prerequisite to prevent flattening of primary hepatocytes in
short-term well-based culture (LeCluyse 2001). Likewise,
forming tight cords of hepatocytes within a perfused
microchannel and patterning hepatocyte islands with sur-
rounding fibroblasts has been shown to maintain proper phe-
notypes for long-term culture (Bhatia et al. 1998).
Compaction allows for proper spacing of hepatocytes tomimic
the cellular structure of a liver acinus. To supply the liver, the
portal vein and hepatic artery branch 8-10 times to feed hex-
agonal structures called Kiernan lobules. Inside lobules, blood
flows from portal venules and hepatic arterioles to the central
vein of a lobule through sinusoids as plasma is filtered by
sinusoidal endothelial cells before being engulfed by hepato-
cytes.Within the lobules are single layers of hepatocytes, often
one cell thick. Fifty percent of the hepatocytes cell surface is
shared with other hepatocytes. Tight junctions coordinated
from cell to cell form bile canaliculi, which aggregate into a
bile ductile (Arias et al. 2009). By culturing hepatocytes in a
microenvironment that prevents them from spreading, and
instead encouraging formation of units several cells across
and 50-100 cells long, it is possible the MBD is effectively
re-creating the spatial features of a liver acinus. While the
exact mechanism of action of the MBD requires further inves-
tigation, this demonstrates that the spatial constriction of the
channel alone, without perfusion, co-cultures, elaborate
extracellular matrices or media components, is sufficient to
prevent hepatocyte spreading. This understanding, especially
its simplicity, is invaluable in the design of both micro-scale
liver models, as well as larger liver-assist type devices.
It is important to note that the cell density was kept constant
between the different conditions, to eliminate the role of cell-
aggregation as a contributing factor to the phenotype. The cell
density in well cultures and different device architectures was
kept constant at 150,000 cells/cm2. Moreover, cells seeded in
the MBD spread out and adhered well to the collagen-coated
glass substrate, and only began to form aggregates a few days
after seeding, as result of active remodeling by the cells
(Fig. 2e). Though this remodeling resulted in a discontinuous
layer of cells that do not appear closely packed, their cuboidal
morphology appears key to their phenotype, consistent with
previous data (Evenou et al. 2010). It is possible that high
enough cell densities can lead to a sustained phenotype
(Dembélé et al. 2014). In our hands, higher cell densities up
to 300,000 cells/cm2 phenotypes did not improve cell pheno-
type in well cultures (Fig. S4). While much higher densities
can maintain stable phenotypes, as in the case of spheroids
(Kikuchi et al. 2009; Lee et al. 2004; Miranda et al. 2009;
Thoma et al. 2005; Evenou et al. 2010), such systems can be
difficult to produce, image and handle, and pose practical
challenges for multiplexing.Our MBD offers a substitute for
well-based attached hepatocyte culture and is simple to im-
plement and analyze.
3.3 HLSEC-hepatocyte co-culture under static and perfused
media
As there are at least seven distinct cell types in liver (hepato-

















Fig. 4 Spatial confinement is
necessary to maintain hepatocyte
phenotype. (a Devices with
decreasingly complex
architecture were seeded with
FHH’s, and then modified post-
seed to yield either a patterned
strip of cells (“patterned”) or cells
confined in an open channel
within a well (“confined”).
(b) Confined hepatocytes achieve
stable albumin expression, but
patterned hepatocytes produce
much less albumin. Error bars
represent SEM (n=3).
(c Hepatocytes within the walled
device are spatially confined to
the channel, but line-patterned
hepatocytes are able to spread
beyond their initial seeding
pattern (white arrow). Scale bars
represent 100 μm
Biomed Microdevices (2014) 16:727–736 733
lymphocytes, dendritic cells, and stellate cells) and hepato-
cytes alone are not able to complete all the functions of the
liver (Arias et al. 2009), the ability to co-culture multiple liver
cells types is important to achieve a more complete liver
model that reproduces many of the essential functions of the
liver. To demonstrate the ability of the device to support
multiple cell types, we employed the bilayer architecture to
investigate juxtaposing the hepatocytes with human liver si-
nusoidal endothelial cells (HLSEC’s). Endothelial cells have
been shown to support both hepatocyte cell line and primary
hepatocyte phenotypes (Ohno et al. 2008; Lee et al. 2004).
The addition of endothelial cells would also aid in developing
a perfused system, as they would (along with the membrane)
serve as a barrier that discourages flow from crossing from the
top to the bottom channel, protecting the hepatocytes from
excessive shear. To develop this vascularized device, we used
the HC-04 hepatoma cell line, as cell lines are an efficient cell
source for prototyping (Materne et al. 2013). Donor-specific
lots of HLSEC’s were confirmed for primary phenotypes via
characterization for LDL uptake and Tumor Necrosis Factor
alpha-induced expression of ICAM and E-selectin. HLSEC
culture was optimized to include shaking the starter flask of
HLSEC’s overnight in an orbital shaker, having the effect of
aligning the cells to shear stress before being seeded into the
upper channel (Fig. S5).
While HC-04 cultured by themselves did not survive under
perfusion for more than 3 days, the presence of vascular
channels increased the ability of HC-04 to tolerate flow
(Fig. 5). This inivestigation allow us to us to establish three
basic requirements for HC-04 survival under flow, which
were extrapolated for FHH. First, hepatocytes were perfused
with media harvested from a culture flask, such that necessary
cytokines or other extracellular factors can be maintained at
appropriate concentration during perfusion. Second, estab-
lishing a monolayer of HLSEC’s in the upper, perfused
channel prior to hepatocyte seeding contributed to culture
longevity under flow. It is worth noting that post-
experiment staining revealed no HLSEC’s remaining in the
upper channel. The endothelial layer likely served to protect
the hepatocytes from shear stress, gradually pulling off from
the membrane while hepatocytes simultaneously were
adapting to steadily increasing shear (Fig. 5b). This points
to the challenges associated with culturing microvascular
endothelial cells (which are generally less robust than other
endothelial cells) in microfluidic channels, particularly on
porous PDMS membranes. More studies are required to
elucidate proper conditions for culturing these cells under
shear. Third, we established the upper limit for flow rates
that the hepatocytes can tolerate. This was exceptionally low
in the case of HC-04 (2.5 μL/h, equivalent to a shear stress of
0.003 dyn/cm2 at the cell surface), indicating a loss of shear
tolerance, likely due to the HC-04 cell line being adapted to
static conditions over many passages. FHH’s were more
tolerant, and were able to be perfused at 137 μL/h (equivalent
to a shear stress of 0.1 dyn/cm2 at the cells surface), provided
they were first cultured under static conditions to allow them
enough time to attach and remodel their microenvironment






Fig. 5 Device co-culture and perfusion. (a) Merged Z-stack through the
co-culture device, green: HC-04, red: HLSEC, blue: DNA. (b) Schematic
of (a) showing HLSEC’s in the upper channel co-cultured with HC-04
hepatocytes in the lower channel. (c) Three-dimensional rendering of (a).
(d) HC-04 cultured in static media in the lower chamber for three weeks
show overgrowth and death, but many live cells in the periphery of the cell
mass in the channel. (e) HC-04 cultured in the lower channel under media
perfusion at 2.5 μL/h for one week. HLSECwere seeded in the top channel
at the start of the experiment (not imaged). (f) FHH’s cultured in the lower
channel for three weeks under static media. (g) FHH’s after 12 days under
static media followed by 10 days under perfusion at 137 μL/h. (d–g)
Green: live, red: dead, blue: DNA. All bars represent 100 μm
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A liver culture model featuring media perfusion is inher-
ently more phenotypic because the liver is not a static organ.
Previous research has shown the importance of flow for both
the parenchymal and non-parenchymal aspects of the liver
culture model. Healthy hepatocytes require a relatively large
influx of oxygen difficult to achieve by diffusion alone,
highlighting the importance of perfused oxygen-rich media
(Domansky et al. 2010). Additionally, primary liver sinusoidal
endothelial cells lose important phenotypes and features, such
as sieve plates, after a few days in culture (Daneker et al.
1998). Efforts to maintain endothelial structure and pheno-
types in vitro have focused on identifying proper perfusion,
extracellular matrix, and cytokine gradients (Kim et al. 2013,
Sato and Ohashi 2005). While our MBD is capable of
perfused cell culture, much more optimization is needed to
obtain in vivo-like vascular structures within the MBD. We
have estimated the oxygen flux through theMBD to be greater
than that in a typical wellplate culture, negating the need for
flow to meet oxygen demands. Moreover, static culture is
advantageous because there is no need for syringe pumps and
tubing. The MBD’s compatibility with different cell types and
flow conditions is important for assessing which biological
and mechanical components are necessary for a fully opti-
mized liver model.
4 Conclusion
Here we present a simple and flexible liver model capable of
supporting human hepatocytes and their phenotypes for at
least three weeks of continuous culture. When hepatocytes
are cultured in the MBD alone in static media, spatial con-
finement provided by the channel walls promotes albumin
production, factor IX production, expression of cytochrome
P450 enzymes, and formation of functional bile canaliculi,
indicating that hepatocytes are maintaining functionality and
demonstrating the potential of this liver model. As organ-on-
a-chip models are often complex and tailored for specific cell
types or organ models, this device demonstrates flexibility in
that either hepatic cell lines or primary hepatocytes can be
seeded into the parenchymal chamber, and if needed, addi-
tional cell types such as sinusoidal endothelial cells, stellate
cells, or Kupffer cells can be utilized for co-culture effects and
as potential cues for improved long-term liver culture.
Furthermore, the MBD can be perfused or kept static, depend-
ing on the ideal culture conditions for each cell type within the
MBD. Further studies with different media perfusion rates,
supporting cell types, and complex extracellular matrices can
elucidate and measure the incremental improvement each has
on in vitro liver models. These findings are essential to
development of a long-term, phenotypic, reproducible and
multiplexed liver disease model
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